References
- Cedeno-Laurent F, Dimitroff CJ. Galectin-1 research in T cell immunity: past, present and future. Clin Immunol 2012;142:107–16.
- Camby I, Le Mercier M, Lefranc F, Kiss R. Galectin-1: a small protein with major functions. Glycobiology 2006;16:137R–57R.
- Le QT, Shi G, Cao H, Nelson DW, Wang Y, Chen EY, et al. Galectin-1: a link between tumor hypoxia and tumor immune privilege. J Clin Oncol 2005;23:8932–41.
- Gillenwater A, Xu XC, el-Naggar AK, Clayman GL, Lotan R. Expression of galectins in head and neck squamous cell carcinoma. Head Neck 1996;18:422–32.
- Saussez S, Camby I, Toubeau G, Kiss R. Galectins as modulators of tumor progression in head and neck squamous cell carcinomas. Head Neck 2007;29:874–84.
- Rubinstein N, Alvarez M, Zwirner NW, Toscano MA, Ilarregui JM, Bravo A, et al. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; a potential mechanism of tumor-immune privilege. Cancer Cell 2004;5:241–51.
- Win KT, Lee SW, Huang HY, Lin LC, Lin CY, Hsing CH, et al. Nicotinamide N-methyl transferase overexpression is associated with Akt phosphorylation and indicates worse prognosis in patients with nasopharyngeal carcinoma. Tumour Biol 2013;34:3923–31.
- Kao YC, Lee SW, Lin LC, Chen LT, Hsing CH, Hsu HP, et al. Fatty acid synthase overexpression confers an independent prognosticator and associates with radiation resistance in nasopharyngeal carcinoma. Tumour Biol 2013;34:759–68.
- Cancer Registry Annual Report. Taiwan, ROC: Department of Health; 2009. https://cris.hpa.gov.tw/pagepub/Home.aspx?itemNo=cr.q.10. in Chinese last accessed October 28, 2013.
- Chen L, Mao YP, Xie FY, Liu LZ, Sun Y, Tian L, et al. The seventh edition of the UICC/AJCC staging system for nasopharyngeal carcinoma is prognostically useful for patients treated with intensity-modulated radiotherapy from an endemic area in China. Radiother Oncol 2012;104:331–7.
- Sun DP, Lin CY, Tian YF, Chen LT, Lin LC, Lee SW, et al. Clinicopathological significance of HuR expression in gallbladder carcinoma: with special emphasis on the implications of its nuclear and cytoplasmic expression. Tumour Biol 2013;34:3059–69.
- Jung EJ, Moon HG, Cho BI, Jeong CY, Joo YT, Lee YJ, et al. Galectin-1 expression in cancer-associated stromal cells correlates tumor invasiveness and tumor progression in breast cancer. Int J Cancer 2007;120:2331–8.
- Kohrenhagen N, Volker HU, Kapp M, Dietl J, Kammerer U. Increased expression of galectin-1 during the progression of cervical neoplasia. Int J Gynecol Cancer 2006;16:2018–22.
- Chiang WF, Liu SY, Fang LY, Lin CN, Wu MH, Chen YC, et al. Overexpression of galectin-1 at the tumor invasion front is associated with poor prognosis in early-stage oral squamous cell carcinoma. Oral Oncol 2008;44:325–34.
- Szoke T, Kayser K, Baumhakel JD, Trojan I, Furak J, Tiszlavicz L, et al. Prognostic significance of endogenous adhesion/growth-regulatory lectins in lung cancer. Oncology 2005;69:167–74.
- Grutzmann R, Pilarsky C, Ammerpohl O, Lüttges J, Böhme A, Sipos B, et al. Gene expression profiling of microdissected pancreatic ductal carcinomas using high-density DNA microarrays. Neoplasia 2004;6:611–22.
- Gabius HJ, Andre S, Gunsenhauser I, Kaltner H, Kayser G, Kopitz J, et al. Association of galectin-1- but not galectin-3-dependent parameters with proliferation activity in human neuroblastomas and small cell lung carcinomas. Anticancer Res 2002;22:405–10.
- Tang CE, Tan T, Li C, Chen ZC, Ruan L, Wang HH, et al. Identification of Galectin-1 as a novel biomarker in nasopharyngeal carcinoma by proteomic analysis. Oncol Rep 2010;24:495–500.
- Wu MH, Hong TM, Cheng HW, Pan SH, Liang YR, Hong HC, et al. Galectin-1-mediated tumor invasion and metastasis, up-regulated matrix metalloproteinase expression, and reorganized actin cytoskeletons. Mol Cancer Res 2009;7:311–18.
- Lin YS, Lin LC, Huang MH, Huang AJ, Huang YT. Down-regulation of gp130 in nasopharyngeal carcinoma. Am J Rhinol Allergy 2009;23:28–32.